Abstract
Thiazolidinediones (TZDs) are used as antidiabetic therapy. The purpose of the present study was to examine whether the TZD rosiglitazone has direct actions on pancreatic beta-cells that contribute to its overall effects. Effects of acute and prolonged (48 h) exposure to rosiglitazone, as a model glitazone compound, were assessed in clonal pancreatic BRIN-BD11 beta-cells maintained in standard, glucotoxic and lipotoxic cultures. In acute 20-min incubations, rosiglitazone (0.2-100 M) did not alter basal or glucose-stimulated insulin secretion. However, rosiglitazone (6.25 M) enhanced (p
Original language | English |
---|---|
Pages (from-to) | 244-249 |
Number of pages | 6 |
Journal | Hormone and Metabolic Research |
Volume | 43 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2011 |
Keywords
- insulin secretion
- rosiglitazone
- beta-cell
- AMPK
- PPAR-γ